Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Saved in:
| Title: | Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. |
|---|---|
| Authors: | Delaloge, S.1 suzette.delaloge@gustaveroussy.fr, Pérol, D.2, Courtinard, C.3, Brain, E.4, Asselain, B.3, Bachelot, T.2, Debled, M.5, Dieras, V.4, Campone, M.6, Levy, C.7, Jacot, W.8, Lorgis, V.9, Veyret, C.10, Dalenc, F.11, Ferrero, J. M.12, Uwer, L.13, Kerbrat, P.14, Goncalves, A.15, Mouret-Reynier, M. A.16, Petit, T.17 |
| Source: | Annals of Oncology. Sep2016, Vol. 27 Issue 9, p1725-1732. 8p. 1 Diagram, 2 Charts, 2 Graphs. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 117765813 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Delaloge%2C+S%2E%22">Delaloge, S.</searchLink><relatesTo>1</relatesTo><i> suzette.delaloge@gustaveroussy.fr</i><br /><searchLink fieldCode="AR" term="%22Pérol%2C+D%2E%22">Pérol, D.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Courtinard%2C+C%2E%22">Courtinard, C.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Brain%2C+E%2E%22">Brain, E.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Asselain%2C+B%2E%22">Asselain, B.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Bachelot%2C+T%2E%22">Bachelot, T.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Debled%2C+M%2E%22">Debled, M.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Dieras%2C+V%2E%22">Dieras, V.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Campone%2C+M%2E%22">Campone, M.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Levy%2C+C%2E%22">Levy, C.</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Jacot%2C+W%2E%22">Jacot, W.</searchLink><relatesTo>8</relatesTo><br /><searchLink fieldCode="AR" term="%22Lorgis%2C+V%2E%22">Lorgis, V.</searchLink><relatesTo>9</relatesTo><br /><searchLink fieldCode="AR" term="%22Veyret%2C+C%2E%22">Veyret, C.</searchLink><relatesTo>10</relatesTo><br /><searchLink fieldCode="AR" term="%22Dalenc%2C+F%2E%22">Dalenc, F.</searchLink><relatesTo>11</relatesTo><br /><searchLink fieldCode="AR" term="%22Ferrero%2C+J%2E+M%2E%22">Ferrero, J. M.</searchLink><relatesTo>12</relatesTo><br /><searchLink fieldCode="AR" term="%22Uwer%2C+L%2E%22">Uwer, L.</searchLink><relatesTo>13</relatesTo><br /><searchLink fieldCode="AR" term="%22Kerbrat%2C+P%2E%22">Kerbrat, P.</searchLink><relatesTo>14</relatesTo><br /><searchLink fieldCode="AR" term="%22Goncalves%2C+A%2E%22">Goncalves, A.</searchLink><relatesTo>15</relatesTo><br /><searchLink fieldCode="AR" term="%22Mouret-Reynier%2C+M%2E+A%2E%22">Mouret-Reynier, M. A.</searchLink><relatesTo>16</relatesTo><br /><searchLink fieldCode="AR" term="%22Petit%2C+T%2E%22">Petit, T.</searchLink><relatesTo>17</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. Sep2016, Vol. 27 Issue 9, p1725-1732. 8p. 1 Diagram, 2 Charts, 2 Graphs. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=117765813 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/annonc/mdw260 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 8 StartPage: 1725 Titles: – TitleFull: Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Delaloge, S. – PersonEntity: Name: NameFull: Pérol, D. – PersonEntity: Name: NameFull: Courtinard, C. – PersonEntity: Name: NameFull: Brain, E. – PersonEntity: Name: NameFull: Asselain, B. – PersonEntity: Name: NameFull: Bachelot, T. – PersonEntity: Name: NameFull: Debled, M. – PersonEntity: Name: NameFull: Dieras, V. – PersonEntity: Name: NameFull: Campone, M. – PersonEntity: Name: NameFull: Levy, C. – PersonEntity: Name: NameFull: Jacot, W. – PersonEntity: Name: NameFull: Lorgis, V. – PersonEntity: Name: NameFull: Veyret, C. – PersonEntity: Name: NameFull: Dalenc, F. – PersonEntity: Name: NameFull: Ferrero, J. M. – PersonEntity: Name: NameFull: Uwer, L. – PersonEntity: Name: NameFull: Kerbrat, P. – PersonEntity: Name: NameFull: Goncalves, A. – PersonEntity: Name: NameFull: Mouret-Reynier, M. A. – PersonEntity: Name: NameFull: Petit, T. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: Sep2016 Type: published Y: 2016 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 27 – Type: issue Value: 9 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |